11/06/11
Ocera Therapeutics Presents Data from First Human Studies with OCR-002, an Ammonia Scavenger Evaluated for the Treatment of Hyperammonemia and Hepatic Encephalopathy
08/24/11
Ocera Therapeutics Announces that Data from its Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AST-120 in Non-Constipating Irritable Bowel Syndrome was Published in Alimentary Pharmacology & Therapeutics
12/15/10
Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
05/03/10
Data Presented by Ocera Therapeutics at DDW Demonstrates that Neurocognitive Impairment is Highly Prevalent in Ambulatory Cirrhotic Patients
05/03/10
Ocera Therapeutics Demonstrates Proof of Principle for the Use of AST-120 in the Treatment of Non-Constipating Irritable Bowel Syndrome